AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12034044 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐alpha2b (IFN‐alpha2b) 5 MU three times a week for 24 weeks
Number of subjects: 76
Study 12034044 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 76
Study 9919322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NT) combined with interpersonal psychotherapy (IPT)
Number of subjects: 180
Study 9919322 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance treatment with Nortriptyline (NT)
Number of subjects: 180
Study 9919322 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with interpersonal psychotherapy (IPT)
Number of subjects: 180
Study 9919322 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance monthly IPT (combined with NT or placebo)
Number of subjects: 180
Study 8787856 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary high-dose rate 125I implant
Number of subjects: 0
Study 8787856 — intervention group
Group type: COMPARATOR
Intervention: Permanent low-dose rate 125I implant
Number of subjects: 0
Study 8787856 — intervention group
Group type: COMPARATOR
Intervention: Quality assurance methodology
Number of subjects: 0
Study 8787856 — intervention group
Group type: COMPARATOR
Intervention: Future adjuvant application of hyperthermia
Number of subjects: 0
Study 1704550 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 10
Study 1704550 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing with AV interval 75 msec
Number of subjects: 10
Study 1704550 — intervention group
Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 10
Study 113716 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprenil and Chelaton Polfa (radiosensitizers)
Number of subjects: 0
Study 113716 — intervention group
Group type: COMPARATOR
Intervention: Control group (no radiosensitizers)
Number of subjects: 0
Study 31077299 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline alpha‐tocopherol (fifth quintile [Q5])
Number of subjects: 22881
Study 31077299 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alpha‐tocopherol at 3 years (Q5)
Number of subjects: 22881
Study 31077299 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower serum alpha‐tocopherol at baseline with greater increases at 3 years (third tertile)
Number of subjects: 22881
Study 30857609 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone 4 mg with ropivacaine 0.75% (3 ml) and saline (1 ml)
Number of subjects: 24
Study 30857609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 4 mg with perineural saline (1 ml)
Number of subjects: 24
Study 30857609 — intervention group
Group type: COMPARATOR
Intervention: Control group with perineural saline (1 ml) and intravenous saline (1 ml)
Number of subjects: 24
Study 27207016 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive model constructed using aspartate aminotransferase, HBsAg, platelet, and albumin as predictors
Number of subjects: 298
Study 27207016 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive model with a cut-off point of -0.96
Number of subjects: 298
Study 27207016 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive model with a cut-off point of 0.96
Number of subjects: 298
Study 26507458 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam + modulated electro-hyperthermia
Number of subjects: 12
Study 26507458 — intervention group
Group type: COMPARATOR
Intervention: Nefopam without hyperthermia
Number of subjects: 12
Study 23450051 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone therapy
Number of subjects: 111
Study 23450051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 21073895 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network for predicting significant fibrosis (ANN-SF)
Number of subjects: 362
Study 19475410 — intervention group
Group type: EXPERIMENTAL
Intervention: NaP + laxative
Number of subjects: 35
Study 19475410 — intervention group
Group type: COMPARATOR
Intervention: NaP
Number of subjects: 35
Study 19475410 — intervention group
Group type: COMPARATOR
Intervention: PEG
Number of subjects: 35
Study 17373902 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted or biological therapies
Number of subjects: 0
Study 17373902 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer chemotherapeutic agents
Number of subjects: 0
Study 14729785 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid (UA) administration
Number of subjects: 0
Study 14729785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11552018 — intervention group
Group type: EXPERIMENTAL
Intervention: OXC 2400 mg/day
Number of subjects: 143
Study 11552018 — intervention group
Group type: COMPARATOR
Intervention: OXC 300 mg/day
Number of subjects: 143
Study 9747173 — intervention group
Group type: EXPERIMENTAL
Intervention: PdB (new surgical instrument)
Number of subjects: 100
Study 9747173 — intervention group
Group type: COMPARATOR
Intervention: No PdB (control group)
Number of subjects: 100
Study 10138808 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mail intervention (Call Fast, Call 911 campaign) - six direct mail pieces over a 1-year period
Number of subjects: 130000
Study 10138808 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 130000
Study 3050248 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration biopsy technique
Number of subjects: 21
Study 30429127 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate diet (60%, n=54)
Number of subjects: 164
Study 30429127 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate carbohydrate diet (40%, n=53)
Number of subjects: 164
Study 30429127 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (20%, n=57)
Number of subjects: 164
Study 30429127 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (20%)
Number of subjects: 164
Study 27913910 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no price display)
Number of subjects: 1205
Study 27913910 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Median Price arm
Number of subjects: 1205
Study 27913910 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired Internal/External Median Prices arm
Number of subjects: 1205
Study 26711384 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited margins IMRT with temozolomide chemotherapy
Number of subjects: 50
Study 26711384 — intervention group
Group type: COMPARATOR
Intervention: Routine margins IMRT with temozolomide chemotherapy
Number of subjects: 50
Study 23275036 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (AZ) 1,000 mg intravenous administration (single dose)
Number of subjects: 32
Study 20644497 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus crispatus CTV‐05 (LACTIN‐V) administered by a vaginal applicator at 2 × 10 colony‐forming units (cfu)/dose for 5 days followed by weekly application for 2 weeks
Number of subjects: 24
Study 20644497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17851681 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg/kg
Number of subjects: 22
Study 17851681 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 22
Study 15735098 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-isoflavone soy protein isolate (SPI)
Number of subjects: 35
Study 15735098 — intervention group
Group type: EXPERIMENTAL
Intervention: High-isoflavone soy protein isolate (SPI)
Number of subjects: 35
Study 15735098 — intervention group
Group type: COMPARATOR
Intervention: Milk protein isolate (MPI)
Number of subjects: 35
Study 12749389 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D active-surface border detection system
Number of subjects: 9
Study 12749389 — intervention group
Group type: COMPARATOR
Intervention: Manual tracing by four experienced observers
Number of subjects: 9
Study 10533344 — intervention group
Group type: EXPERIMENTAL
Intervention: Documentation-and-payment group
Number of subjects: 200
Study 10533344 — intervention group
Group type: COMPARATOR
Intervention: Documentation-only group
Number of subjects: 200
Study 10533344 — intervention group
Group type: COMPARATOR
Intervention: Silent control group
Number of subjects: 200
Study 8690121 — intervention group
Group type: EXPERIMENTAL
Intervention: GH + hCG protocol: 4 IU SC GH daily 8 days before and throughout the hCG phase
Number of subjects: 8
Study 8690121 — intervention group
Group type: EXPERIMENTAL
Intervention: plain hCG protocol: 1,500 IU IM three times every other day
Number of subjects: 8
Study 8690121 — intervention group
Group type: COMPARATOR
Intervention: placebo + hCG: substitution of GH by NaCL 0.9%
Number of subjects: 8
Study 1911739 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐4 9 micrograms
Number of subjects: 36
Study 1911739 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐4 25 micrograms
Number of subjects: 36
Study 1911739 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐4 50 micrograms
Number of subjects: 36
Study 1911739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 6791938 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin treatment (25 mg x 4 daily)
Number of subjects: 22
Study 6791938 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 22
Study 6791938 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 22
Study 6791938 — intervention group
Group type: COMPARATOR
Intervention: Alcohol addicts with diarrhoea or steatorrhoea
Number of subjects: 22
Study 6791938 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with chronic diarrhoea
Number of subjects: 22
Study 6791938 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with intermittent diarrhoea classified as irritable bowel syndrome
Number of subjects: 22
Study 31725142 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g intravenous (IV) tranexamic acid given 1 to 3 hours after delivery
Number of subjects: 0
Study 28250047 — intervention group
Group type: EXPERIMENTAL
Intervention: Job rotation programme
Number of subjects: 0
Study 28250047 — intervention group
Group type: COMPARATOR
Intervention: Control group (ergonomic training only)
Number of subjects: 0
Study 26340264 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA plus EPA (2 g/day)
Number of subjects: 100
Study 26340264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 23657962 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan + Amlodipine (fixed combination)
Number of subjects: 0
Study 23657962 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of Olmesartan + Amlodipine
Number of subjects: 0
Study 23657962 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate administration of Olmesartan + Amlodipine
Number of subjects: 0
Study 21418836 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group
Number of subjects: 128
Study 21418836 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study 19920423 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) guidance
Number of subjects: 40
Study 19920423 — intervention group
Group type: COMPARATOR
Intervention: Electrical stimulation (ES) guidance
Number of subjects: 40
Study 16963038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI)
Number of subjects: 95
Study 16963038 — intervention group
Group type: COMPARATOR
Intervention: Standard insemination (IVF)
Number of subjects: 95
Study 16279219 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (verum group)
Number of subjects: 0
Study 16279219 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 16279219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (verum and placebo)
Number of subjects: 0
Study 11256536 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-inhibitor therapy
Number of subjects: 0
Study 8988997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine 0.50 mg/kg
Number of subjects: 5
Study 8988997 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5
Study 8501270 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigator with a magnetic device
Number of subjects: 54
Study 8501270 — intervention group
Group type: COMPARATOR
Intervention: Unmagnetized irrigator (Control)
Number of subjects: 54
Study 3326689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bay‐m‐1099 (50 mg)
Number of subjects: 31
Study 3326689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 3326689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bay‐o‐1248 (20 mg or 10 mg)
Number of subjects: 31
Study 29327085 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 47
Study 29327085 — intervention group
Group type: COMPARATOR
Intervention: Education/Support (Control)
Number of subjects: 47
Study 26707493 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal parent training
Number of subjects: 151
Study 26707493 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 151
Study 25581660 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking-reduction intervention
Number of subjects: 254
Study 25581660 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HCV coinfected patients
Number of subjects: 254
Study 25581660 — intervention group
Group type: EXPERIMENTAL
Intervention: Effort to restrict drinking
Number of subjects: 254
Study 25581660 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of medical risk
Number of subjects: 254
Study 25581660 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported effort to restrict drinking
Number of subjects: 254
Study 22840988 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous hamstring tendon
Number of subjects: 147
Study 22840988 — intervention group
Group type: COMPARATOR
Intervention: Fresh-frozen allograft anterior tibialis tendon
Number of subjects: 147
Study 20423998 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg twice daily p.o. for a minimum of 14 days)
Number of subjects: 13
Study 20423998 — intervention group
Group type: COMPARATOR
Intervention: Control (not receiving a Cox inhibitor)
Number of subjects: 13
Study 17161126 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio computer-assisted self-interviewing (ACASI)
Number of subjects: 655
Study 17161126 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face (FTF) interview
Number of subjects: 655
Study 15370247 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil 0.1 mg/kg/day indefinitely
Number of subjects: 210
Study 15370247 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil 0.1 mg/kg/day plus theophylline 200 mg bid, orally
Number of subjects: 210
Study 11292522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 234
Study 11292522 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 234
Study 11292522 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 9034682 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based metalworking fluids (MWF) applied with Finn Chambers for 1 day, then reapplied for 2 days
Number of subjects: 0
Study 9034682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative irritant contact dermatitis induced using a repetitive irritation test for 2 weeks (6 hours per day, omitting weekends)
Number of subjects: 0
Study 9034682 — intervention group
Group type: EXPERIMENTAL
Intervention: D1/D3 model as a predictive test of MWF irritancy
Number of subjects: 0
Study 9034682 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiological data correlation
Number of subjects: 0
Study 7911011 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl glutamic acid (NAAGA) (Rhinaaxia)
Number of subjects: 230
Study 7911011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 7911011 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 230
Study 3330527 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine
Number of subjects: 0
Study 3330527 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study 30524135 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR) analysis
Number of subjects: 3108
Study 30524135 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall-by-Genotype (RbG) analysis
Number of subjects: 3108
Study 30524135 — intervention group
Group type: EXPERIMENTAL
Intervention: RbG analysis
Number of subjects: 3108
Study 27566117 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Life Skills (CLS)
Number of subjects: 135
Study 27566117 — intervention group
Group type: COMPARATOR
Intervention: Usual services
Number of subjects: 135
Study 24322182 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate 2 g/vitamin D₃ 1000 IU daily
Number of subjects: 518
Study 24322182 — intervention group
Group type: COMPARATOR
Intervention: Strontium ranelate 2 g daily
Number of subjects: 518
Study 24322182 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 518
Study 21939611 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (olanzapine, risperidone, quetiapine)
Number of subjects: 361
Study 21939611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 20137765 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (IG, Lantus)
Number of subjects: 0
Study 20137765 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir (ID, Levemir)
Number of subjects: 0
Study 20137765 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (IG)
Number of subjects: 0
Study 20137765 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir (ID)
Number of subjects: 0
Study 17609679 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 124
Study 17609679 — intervention group
Group type: COMPARATOR
Intervention: First-generation antipsychotics (FGAs)
Number of subjects: 124
Study 16029567 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2.5 mg/kg intravenous injection
Number of subjects: 200
Study 16029567 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 microg intravaginally
Number of subjects: 200
Study 15273525 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation program (12 sessions over 4 weeks)
Number of subjects: 20
Study 15273525 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 20
Study 11374267 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions for shoulder, elbow, and finger exercises
Number of subjects: 30
Study 11374267 — intervention group
Group type: COMPARATOR
Intervention: Occupational therapy
Number of subjects: 30
Study 9150838 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled furosemide
Number of subjects: 16
Study 9150838 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled amiloride
Number of subjects: 16
Study 9150838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7524885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 0
Study 7524885 — intervention group
Group type: COMPARATOR
Intervention: Normal adults
Number of subjects: 0
Study 3586818 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming without earplugs
Number of subjects: 85
Study 3586818 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming with earplugs
Number of subjects: 85
Study 3586818 — intervention group
Group type: EXPERIMENTAL
Intervention: No swimming
Number of subjects: 85
Study 30633595 — intervention group
Group type: EXPERIMENTAL
Intervention: LP loaded SLMs with SRP
Number of subjects: 16
Study 30633595 — intervention group
Group type: COMPARATOR
Intervention: SRP only
Number of subjects: 16
Study 28860128 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1 μg/kg/min)
Number of subjects: 12
Study 28860128 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 12
Study 26817183 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A split injection sites
Number of subjects: 31
Study 26817183 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin A non-split injection sites
Number of subjects: 31
Study 23241943 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 738
Study 23241943 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 738
Study 23241943 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-rated severity
Number of subjects: 738
Study 21153533 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning to a highly hydrolysed formula for 6 to 8 months
Number of subjects: 2160
Study 21153533 — intervention group
Group type: COMPARATOR
Intervention: Standard cow's milk formula
Number of subjects: 2160
Study 21153533 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall retention rate
Number of subjects: 2160
Study 21153533 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol compliance
Number of subjects: 2160
Study 18082499 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 258
Study 18082499 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 258
Study 16481083 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute alcohol intoxication
Number of subjects: 0
Study 16481083 — intervention group
Group type: COMPARATOR
Intervention: Sober participants
Number of subjects: 0
Study 16481083 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional cues
Number of subjects: 0
Study 16481083 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about the experimental purpose
Number of subjects: 0
Study 16481083 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study 14564379 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure delivered by head helmet (CPAPH)
Number of subjects: 8
Study 14564379 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure delivered by face mask (CPAPM)
Number of subjects: 8